Avalo Therapeutics, Inc. Common Stock (AVTX)

Typically moves ±4.76% on earnings

EARNINGS ANALYTICS

event_upcoming Est. Next Earnings: 2026-11-12 ESTIMATED

Avalo Therapeutics, Inc. Common Stock (AVTX) has a 21-report earnings history dating back to Aug 02, 2021. Its average absolute post-earnings move is ±4.76%, and 33.3% of those reactions were positive. Its largest post-earnings gain was +9.59% (Aug 04, 2022) and its largest decline was -14.64% (May 05, 2022). The next earnings report is predicted for 2026-11-12 (estimated).

Earnings reactions

How AVTX moved on each past earnings report.

Up Down

Earnings Impact

Total Earnings

Avg Abs. Movement

±4.76%

Positive %

33.3%

Negative %

66.7%

Historical Earnings Statistics

Date	Timing	Earnings move	SEC Filing
Aug 06, 2026	☀ PRE	-0.69%	open_in_new
May 13, 2026	☀ PRE	-0.63%	open_in_new
May 07, 2026	☽ POST	-6.23%	open_in_new
Mar 23, 2026	☀ PRE	+0.67%	open_in_new
Nov 06, 2025	☀ PRE	-6.16%	open_in_new
Aug 07, 2025	☀ PRE	-0.06%	open_in_new
May 12, 2025	☀ PRE	-5.18%	open_in_new
Mar 20, 2025	☀ PRE	+5.04%	open_in_new
Nov 07, 2024	☀ PRE	-2.9%	open_in_new
Aug 12, 2024	☀ PRE	-12.93%	open_in_new
May 13, 2024	☀ PRE	+1.13%	open_in_new
Nov 09, 2023	☀ PRE	-10.51%	open_in_new
Aug 03, 2023	☀ PRE	-0.05%	open_in_new
May 04, 2023	☽ POST	+6.25%	open_in_new
Mar 29, 2023	☀ PRE	-7.14%	open_in_new
Nov 07, 2022	☀ PRE	+3.56%	open_in_new
Aug 04, 2022	☀ PRE	+9.59%	open_in_new
May 05, 2022	☀ PRE	-14.64%	open_in_new
Mar 02, 2022	☀ PRE	-5.1%	open_in_new
Nov 09, 2021	☽ POST	-1.51%	open_in_new
Aug 02, 2021	☽ POST	+0%	open_in_new

event

Earnings Count

Total earnings in dataset

trending_up

Avg Abs. Movement

±4.76%

Avg % price change on earnings

description

SEC Filings

View

Browse all SEC filings

account_balance

Institutional ownership

Holdings as of Jun 30, 2026 · SEC 13-F

View all 20 →

Funds holding

$247399781

Total value held

Buying

16 added · 4 reduced

Blackrock, Inc.

$80675418 +1234.70%

State Street Corp

$53394024 +3932.28%

Bank Of America Corp /De/

$35367561 +197.64%

Ubs Group Ag

$22343410 NEW BUY

Goldman Sachs Group Inc

$17487993 +1474.42%

SEC Filing Types

description 4

29 chevron_right

description SCHEDULE 13G/A

18 chevron_right

description 144

7 chevron_right

description SCHEDULE 13G

Recent SEC Filings

10 most recent

Form	Date Filed	View on EDGAR
4	20260901	open_in_new SEC.gov
4	20260819	open_in_new SEC.gov
4	20260819	open_in_new SEC.gov
144	20260818	open_in_new SEC.gov
144	20260817	open_in_new SEC.gov
144	20260817	open_in_new SEC.gov
144	20260817	open_in_new SEC.gov
SCHEDULE 13G/A	20260814	open_in_new SEC.gov
SCHEDULE 13G/A	20260814	open_in_new SEC.gov
SCHEDULE 13G/A	20260814	open_in_new SEC.gov

Frequently asked about AVTX earnings

When does Avalo Therapeutics, Inc. Common Stock report earnings next? expand_more

Avalo Therapeutics, Inc. Common Stock (AVTX)'s next earnings date is estimated for 2026-11-12. This is a prediction based on its historical quarterly reporting pattern, not a company-confirmed date.

How much does AVTX stock move after earnings? expand_more

Over 21 reports, AVTX has moved an average of ±4.76% the session after earnings, closing higher 33.3% of the time.

What was AVTX's biggest post-earnings move? expand_more

AVTX's largest post-earnings gain on record was +9.59% on Aug 04, 2022, and its largest decline was -14.64% on May 05, 2022.

Where can I find Avalo Therapeutics, Inc. Common Stock's SEC filings? expand_more

All of Avalo Therapeutics, Inc. Common Stock's SEC filings — 10-K, 10-Q, 8-K and more — are listed in the SEC filings section on this page, each linking to the original document on SEC.gov.